Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

Prior treatment

• They have received chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to study enrollment.
• They have any other co-morbidity or habit that the Investigator believes will interfere with their ability to comply with and complete the study. They are not a candidate for standard of care surgery based on opinion of the surgeon, anesthesiologist, or other consulting physician.

Other illness

• They have a known allergy or reaction to radiographic contrast agents, ICG, or any component of abenacianine.

Other

• They are prisoners, institutionalized individuals, or are unable to consent for themselves.

• Be willing and able to sign the informed consent and comply with study procedures.
• Be at least 18 years of age.
• Be scheduled for or planning to have a surgical resection of a lung lesion or mass with diagnostic and/or curative intent.
• Meet all requirements for the planned surgery based on opinion of the surgeon, anesthesiologist, and/or other consulting physician.
• Be able to meet the following conditions:
  • Female participants must be of non-childbearing potential, or,
  • If of childbearing potential, be non-pregnant or non-lactating and agree to use highly effective contraception from screening through Day 30 after treatment.
  • Male participants, if not surgically sterilized, and if engaging in sexual intercourse with a female partner of childbearing potential, must be willing to use highly effective contraception from screening through 30 days after dosing.
• Have not participated in an interventional clinical trial within the last 30 days.